SCHEMBL891290

SCHEMBL891290

CC(C)c1ccc(C(C)C)[nH]1

nearest known ligand 0.35

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
DAO P14920 1/20 0.35
HMBS P08397 1/20 0.32
HCAR3 P49019 1/20 0.30
HCAR2 Q8TDS4 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6920477 0.82
SCHEMBL13508327 0.80
SCHEMBL12562951 0.80
SCHEMBL10092848 0.76 GPR84 (0.30)
SCHEMBL12180269 0.74 DAO (0.39) DAOHCAR2
SCHEMBL12740601 0.74 GABRA1 (0.35)
SCHEMBL12180533 0.74 DAO (0.39) DAO
SCHEMBL12740587 0.72 KDM4E (0.44) DAOHCAR3HCAR2
SCHEMBL25093855 0.71 GRIN2D (0.39) DAO
SCHEMBL179270 0.70 MMP1 (0.44) DAO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 395 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118239981-A Phosphonite ligand, catalyst and application thereof in hydroformylation reaction 万华化学集团股份有限公司 2024-06-25 CN claimed
US-8362278-B2 Methods for the conversion of a substituted furan to a substituted pyrrole CHEVRON PHILLIPS CHEMICAL COMPANY LP (US) 2013-01-29 US claimed
US-20120083609-A1 METHODS FOR THE CONVERSION OF A SUBSTITUTED FURAN TO A SUBSTITUTED PYRROLE CHEVRON PHILLIPS CHEMICAL COMPANY LP (US) 2012-04-05 US claimed
EP-4737461-A1 NOVEL COMPOUND, PRECURSOR COMPOSITION COMPRISING SAME, AND METHOD FOR MANUFACTURING THIN FILM USING SAME Hansol Chemical Co., Ltd (KR) 2026-05-06 EP disclosed
WO-2025005677-A1 NOVEL COMPOUND, PRECURSOR COMPOSITION COMPRISING SAME, AND METHOD FOR MANUFACTURING THIN FILM USING SAME 주식회사 한솔케미칼 2025-01-02 WO disclosed
CN-118239981-A Phosphonite ligand, catalyst and application thereof in hydroformylation reaction 万华化学集团股份有限公司 2024-06-25 CN disclosed
EP-4359382-A1 TWO-STEP SYNTHESIS OF PYRROLE COMPOUNDS FROM FURAN COMPOUNDS Chevron Phillips Chemical Company LP (US) 2024-05-01 EP disclosed
CN-117881658-A Two-step synthesis of pyrrole compounds from furan compounds 切弗朗菲利浦化学公司 2024-04-12 CN disclosed
US-20230382889-A1 COMPOUNDS FOR INHIBITING KIF18A VOLASTRA THERAPEUTICS, INC. (US) 2023-11-30 US disclosed
US-20230382889-A1 COMPOUNDS FOR INHIBITING KIF18A VOLASTRA THERAPEUTICS, INC. (US) 2023-11-30 US disclosed
US-20230372496-A1 TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS C4 THERAPEUTICS, INC. (US) 2023-11-23 US disclosed
WO-2009120717-A2 PYRIDO [3, 4-B] INDOLES AND METHODS OF USE MEDIVATION TECHNOLOGIES, INC. (US) 2009-10-01 WO disclosed
US-20090239854-A1 Tetracyclic compounds MEDIVATION TECHNOLOGIES, INC. 2009-09-24 US disclosed
WO-2009055828-A1 NEW TETRACYCLIC COMPOUNDS MEDIVATION TECHNOLOGIES, INC. (US) 2009-04-30 WO disclosed
US-20080097078-A1 Antibacterial activity against vancomycin-resistant bacteria SHIONOGI & CO., LTD. (JP) 2008-04-24 US disclosed
US-7291693-B2 Bioerodible conducting materials MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2007-11-06 US disclosed
US-20070238694-A1 Purine compounds and methods of use thereof INOTEK PHARMACEUTICALS CORPORATION (US) 2007-10-11 US disclosed
US-7273940-B2 Catalysts for the polymerization of unsaturated compounds BASELL POLYOLEFINE GMBH (DE) 2007-09-25 US disclosed
US-20050085527-A1 Catalysts for the polymerization of unsaturated compounds EQUISTAR CHEMICALS, LP 2005-04-21 US disclosed
US-6818715-B1 LIGAND SYSTEM FOR NOVEL COMPLEXES CONTAINING LATE TRANSITION METALS WHICH CAN BE USED FOR POLYMERIZATION OF UNSATURATED COMPOUNDS AND GIVE BRANCHED POLYMERS BASF AKTIENGESELLSCHAFT (DE) 2004-11-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230382889-A1 COMPOUNDS FOR INHIBITING KIF18A KIF18A, KIF18B, KIF2C DAO 4673/4885HMBS 4515/4885HCAR3 3889/4885
US-20120083609-A1 METHODS FOR THE CONVERSION OF A SUBSTITUTED FURAN TO A SUBSTITUTED PYRROLE PAH, CPS1, ASNS DAO 23/4885HMBS 50/4885HCAR3 3063/4885
US-20230372496-A1 TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS CRBN, CDR2, MDM2 DAO 1199/4885HMBS 1052/4885HCAR3 3811/4885
US-20070238694-A1 Purine compounds and methods of use thereof PNP, ADORA2A, P2RY1 DAO 357/4885HMBS 737/4885HCAR3 1116/4885
US-20050085527-A1 Catalysts for the polymerization of unsaturated compounds NR0B2, NR4A1, CBR1 DAO 1663/4885HMBS 3354/4885HCAR3 480/4885
US-20080097078-A1 Antibacterial activity against vancomycin-resistant bacteria CSGALNACT1, MON2, NR2C2 DAO 196/4885HMBS 4708/4885HCAR3 126/4885
US-20090239854-A1 Tetracyclic compounds HTR2C, HTR3D, HTR5A DAO 953/4885HMBS 764/4885HCAR3 62/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.